$0.35 EPS Expected for Pacira Biosciences Inc (NASDAQ:PCRX) This Quarter

Equities analysts expect Pacira Biosciences Inc (NASDAQ:PCRX) to post earnings of $0.35 per share for the current fiscal quarter, Zacks reports. Seven analysts have made estimates for Pacira Biosciences’ earnings, with the highest EPS estimate coming in at $0.46 and the lowest estimate coming in at $0.24. Pacira Biosciences reported earnings per share of $0.31 during the same quarter last year, which suggests a positive year over year growth rate of 12.9%. The business is expected to report its next earnings results on Thursday, November 7th.

On average, analysts expect that Pacira Biosciences will report full-year earnings of $1.44 per share for the current fiscal year, with EPS estimates ranging from $1.30 to $1.68. For the next year, analysts forecast that the business will post earnings of $2.07 per share, with EPS estimates ranging from $1.47 to $2.66. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that cover Pacira Biosciences.

Pacira Biosciences (NASDAQ:PCRX) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.41 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.27. Pacira Biosciences had a return on equity of 8.79% and a net margin of 2.04%. The company had revenue of $102.60 million for the quarter, compared to the consensus estimate of $99.92 million. During the same quarter last year, the company earned $0.24 earnings per share. The firm’s revenue for the quarter was up 22.0% compared to the same quarter last year.

Several equities research analysts have weighed in on PCRX shares. Barclays started coverage on Pacira Biosciences in a report on Tuesday, June 11th. They issued an “overweight” rating and a $52.00 price target for the company. Zacks Investment Research raised Pacira Biosciences from a “sell” rating to a “hold” rating and set a $47.00 price target for the company in a report on Friday, August 2nd. Mizuho raised Pacira Biosciences from an “underperform” rating to a “neutral” rating and raised their price target for the stock from $29.00 to $38.00 in a report on Monday, May 6th. BMO Capital Markets decreased their target price on Pacira Biosciences from $46.00 to $43.00 and set a “market perform” rating for the company in a report on Friday, August 9th. Finally, Stifel Nicolaus set a $42.00 target price on Pacira Biosciences and gave the stock a “hold” rating in a report on Friday, August 9th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eight have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $54.13.

NASDAQ PCRX traded up $0.40 during trading on Friday, hitting $39.60. The company’s stock had a trading volume of 9,944 shares, compared to its average volume of 585,952. The company has a current ratio of 8.62, a quick ratio of 7.83 and a debt-to-equity ratio of 0.99. The company has a market capitalization of $1.68 billion, a P/E ratio of 135.59, a PEG ratio of 1.56 and a beta of 1.15. The firm’s 50 day moving average is $42.40. Pacira Biosciences has a fifty-two week low of $35.07 and a fifty-two week high of $55.00.

In related news, CAO Kristen Marie Williams sold 2,529 shares of Pacira Biosciences stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $42.91, for a total transaction of $108,519.39. Following the completion of the transaction, the chief accounting officer now directly owns 19,845 shares in the company, valued at $851,548.95. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Richard Scranton sold 15,510 shares of Pacira Biosciences stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $43.21, for a total value of $670,187.10. Following the transaction, the insider now owns 23,111 shares of the company’s stock, valued at $998,626.31. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 57,990 shares of company stock valued at $2,497,045. 5.80% of the stock is owned by company insiders.

Hedge funds have recently made changes to their positions in the stock. C M Bidwell & Associates Ltd. purchased a new position in Pacira Biosciences during the second quarter valued at approximately $44,000. Tower Research Capital LLC TRC increased its position in shares of Pacira Biosciences by 414.7% in the second quarter. Tower Research Capital LLC TRC now owns 1,436 shares of the company’s stock valued at $63,000 after buying an additional 1,157 shares in the last quarter. Steward Partners Investment Advisory LLC purchased a new stake in shares of Pacira Biosciences in the second quarter valued at approximately $71,000. Amundi Pioneer Asset Management Inc. purchased a new stake in shares of Pacira Biosciences in the first quarter valued at approximately $65,000. Finally, First Mercantile Trust Co. purchased a new stake in shares of Pacira Biosciences in the first quarter valued at approximately $142,000. Institutional investors own 99.89% of the company’s stock.

Pacira Biosciences Company Profile

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.

Featured Article: Earnings Reports

Get a free copy of the Zacks research report on Pacira Biosciences (PCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pacira Biosciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit